<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="367672">
  <stage>Registered</stage>
  <submitdate>2/01/2015</submitdate>
  <approvaldate>2/04/2015</approvaldate>
  <actrnumber>ACTRN12615000312549</actrnumber>
  <trial_identification>
    <studytitle> Efficiency and safety of preoperative Tranexamic acid in reducing perioperative blood loss in elective cesarean section</studytitle>
    <scientifictitle>Efficiency and safety of preoperative Tranexamic acid compared to a placebo in reducing perioperative blood loss in women undergoing elective cesarean section</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>blood loss during and after cesarean section</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Childbirth and postnatal care</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>1 gm tranexamic acid  15 min before CS by intravenous infusion</interventions>
    <comparator>glucose 5% intravenous infusion</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>estimated blood loss (EBL) during and after Cesarean section
Estimated blood loss was calculated according to the following formula:
"EBL = EBV Ã—"  "Preop Hematocrit - Postop Hematocrit" /"Preop Hematocrit" 
EBL: estimated blood loss
EBV: estimated blood volume (ml) = weight (kg) x 85
</outcome>
      <timepoint>24 hours after Cesarean section</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. postoperative hemoglobin, serum assay
</outcome>
      <timepoint>up to 4 weeks after surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>postoperative hematocrit, serum assay</outcome>
      <timepoint>4 weeks after CS</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>platelet count , serum assay </outcome>
      <timepoint>4 weeks after CS</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>needed postoperative ecbolics. needed drugs administered intramuscular</outcome>
      <timepoint>24 hours after CS</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>full-term singleton pregnancies underwent elective lower segment caesarean section </inclusivecriteria>
    <inclusiveminage>19</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>41</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1.prolonged CS (&gt; 90 min according to anesthetic record), 2.anemic patients (Hb &lt; 9 gm %), 
3.presence of maternal medical disorder (e.g. cardiac, renal, hepatic &amp; coagulopathies) or 
4.history of thrombo-embolic events. 
5.known allergy to TA. 
6.Patients with increased risk for obstetric hemorrhage (e.g. antepartum hemorrhage, abnormal placentation, previous history of uterine atony &amp; postpartum hemorrhage, polyhydramnios &amp; uterine fibroids). </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>computer generated random numbers</concealment>
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>False</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/11/2013</anticipatedstartdate>
    <actualstartdate>1/11/2013</actualstartdate>
    <anticipatedenddate>30/11/2014</anticipatedenddate>
    <actualenddate>30/11/2014</actualenddate>
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state>Cairo</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Ahmed Maged</primarysponsorname>
    <primarysponsoraddress>135 King Faisal street Haram Giza.Kasr Alainy medical school.Cairo university Egypt Post code 12151</primarysponsoraddress>
    <primarysponsorcountry>Egypt</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Ahmed maged</fundingname>
      <fundingaddress>135 King Faisal street Haram Giza</fundingaddress>
      <fundingcountry>Egypt</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Moutaz Elsherbiny</sponsorname>
      <sponsoraddress>122 Kasr AlAiny street Cairo. Kasr Alainy medical school.Cairo university Egypt Post code 12398</sponsoraddress>
      <sponsorcountry>Egypt</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A randomized placebo-controlled prospective study involved 200 women undergoing elective LSCS randomized to receive either 1 gm TA 15 min before CS (TA group) or glucose 5% (Placebo group). Complete blood count (CBC) was done before CS and 24 hours later. The pre- and postoperative hematocrit values and maternal weight were used to calculate the estimated blood loss (EBL) during CS which was the primary outcome measure.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Ahmed Maged</name>
      <address>135 King Faisal street Haram Giza Kasr Alainy medical school.Cairo university Egypt Post code 12151</address>
      <phone>+20201005227404</phone>
      <fax />
      <email>prof.ahmedmaged@gmail.com</email>
      <country>Egypt</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Ahmed Maged</name>
      <address>135 King Faisal street Haram Giza Kasr Alainy medical school.Cairo university Egypt Post code 12151</address>
      <phone>+20201005227404</phone>
      <fax />
      <email>prof.ahmedmaged@gmail.com</email>
      <country>Egypt</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Ahmed Maged</name>
      <address>135 King Faisal street Haram Giza Kasr Alainy medical school.Cairo university Egypt Post code 12151</address>
      <phone>+20201005227404</phone>
      <fax />
      <email>prof.ahmedmaged@gmail.com</email>
      <country>Egypt</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Ahmed maged</name>
      <address>135 King Faisal street Haram Giza Postal code 12151</address>
      <phone>+20201005227404</phone>
      <fax />
      <email>prof.ahmedmaged@gmail.com</email>
      <country>Egypt</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>